InnoCan Pharma (TSE:INNO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innocan Pharma has announced promising results from a safety assessment of its LPT-CBD injectable on minipigs, showing excellent tolerance and no adverse effects. This study supports the feasibility of LPT-CBD’s safety evaluations, paving the way for future regulatory milestones in chronic pain treatment.
For further insights into TSE:INNO stock, check out TipRanks’ Stock Analysis page.